POSLUMA

This brand name is authorized in United States.

Active ingredients

The drug POSLUMA contains one active pharmaceutical ingredient (API):

`1`	Flotufolastat ¹⁸F UNII `811W19E3OL` - FLOTUFOLASTAT F-18
	Flotufolastat (¹⁸F) is a radioactive diagnostic agent for intravenous use. Flotufolastat (¹⁸F) binds to PSMA (IC₅₀ = 4.4 nM) expressed on cells, including prostate cancer cells, and is internalized. Prostate cancer cells usually overexpress PSMA. Fluorine-18 is a β+ emitting radionuclide that can be detected using positron emission tomography.
	Read more about Flotufolastat ¹⁸F

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
POSLUMA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
US	FDA, National Drug Code	69932-002

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.